Intellia Therapeutics price target lowered to $47 from $54 at RBC Capital

RBC Capital lowered the firm’s price target on Intellia Therapeutics (NTLA) to $47 from $54 and keeps an Outperform rating on the shares as part of a broader research note previewing Q4 and 2025 earnings in the Biotech sector. Q4 should should come in generally solid across the firm’s large and mid-cap commercial stage companies, helped by seasonal tailwinds, though 2025 expectations may be seeing more optimism than necessarily warranted with a number of launches already baked into numbers and durability of certain core franchises that could challenge certain setups, the analyst tells investors in a research note.